Stock Report

Sathgen Therapeutics Division expands to the U.S. with Launch of Princeton Based Subsidiary

Posted On : 2025-12-17 22:18:17( TIMEZONE : IST )

Godavari Biorefineries Limited (GBL) (BSE: Script Code 544279 | NSE: GODAVARIB), a leading renewable chemicals and bio-based manufacturing conglomerate, has announced the incorporation of Sathgen Therapeutics LLC, a wholly owned step-down subsidiary based in Princeton, New Jersey, USA. This strategic expansion strengthens GBL's clinical-stage biotechnology presence in the United States, with a primary focus on global out-licensing of intellectual property and to build the network to accelerate the drug-development programme.

Sathgen Therapeutics originated from an idea proposed by Dr. Sendurai Mani, an initiative supported by Mr. Samir Somaiya, Chairman and Managing Director of GBL. Together, they laid the foundation for a long-term research effort that has since evolved into an active program focused on discovering and developing multiple novel molecules. Several candidates have shown promising preclinical efficacy, particularly in triple-negative breast cancer (TNBC) and novel class of compounds that inhibit cancer and cancer stem cells in vitro, with strong activity observed in breast and prostate cancer models. Building on this progress, Sathgen has secured patents in US, Europe, China, and other key markets.

"The establishment of Sathgen Therapeutics LLC represents an exciting new chapter in our journey of translating science into meaningful solutions," said Samir Somaiya, Chairman and Managing Director of Godavari Biorefineries Limited. "Fifteen years ago, we asked ourselves a simple but bold question: Why shouldn't India, long known as the pharmacy of the world for its generics, also contribute to original drug discovery? This 'moonshot' approach has guided our efforts across both biorefining and specialty chemicals, and now in breakthrough therapeutics. In this program, we chose to address one of the toughest challenges-triple-negative breast cancer (TNBC), a condition with limited treatment options and difficult prognosis. With contributions from Dr. Mani, particularly in the innovative targeting of cancer stem cells, our aim has been not only to advance scientific understanding but also to meaningfully improve patient outcomes. The opening of our U.S. subsidiary strengthens our ability to bring this vision closer to reality."

"Establishing our U.S. presence gives us a strong platform to engage more closely with partners who can carry our technologies into the next stages of development.," said Dr. Padmaja Ganapathy, CEO, Sathgen Therapeutics USA. "My focus is on building meaningful collaborations that enable the efficient out-licensing and advancement of our discoveries, ensuring they reach the patients who need them most."

"Our scientific approach has always centered on uncovering the biological drivers behind the most aggressive cancers," said Dr. Sendurai Mani, Chief Scientific Officer, Sathgen Therapeutics USA. "By targeting cancer stem cells, we see a strong opportunity to impact conditions like TNBC, where treatment options are limited. With the launch of our U.S. subsidiary, we are excited to deepen our collaborations with global scientific and clinical partners and advance discoveries that have the potential to transform patient outcomes."

Sathgen Therapeutics has also formed a Scientific Advisory Board (SAB) to guide its clinical-development and translational-research strategy. The SAB includes Dr. Razelle Kurzrock, an internationally known authority in precision oncology, immunotherapy, and early-phase clinical trials, and Dr. Massimo Cristofanilli, a leading global expert in metastatic breast cancer and cancer biology. Their combined experience in oncology, patient stratification, and clinical-trial design will play a pivotal role as Sathgen advances its portfolio toward U.S. partnerships and next-phase development.

"At Sathgen, our mission is to translate science into impactful therapies," said Dr. Sangeeta Srivastava, Executive Director of GBL and Head of the Drug Discovery Division. "The formation of our U.S. subsidiary will help accelerate our clinical programs, enable stronger research collaborations, and bring us closer to delivering innovative therapies for patients globally."

GBL's work is guided by a strong commitment to community and responsible development. From education and rural upliftment to environmental stewardship, this values-driven approach remains central as the company expands into advanced biotechnology. With the launch of its U.S. subsidiary, GBL continues to pair scientific progress with a broader purpose-creating meaningful impact for both patients and communities.

Shares of Godavari Biorefineries Limited was last trading in BSE at Rs. 272.55 as compared to the previous close of Rs. 270.25. The total number of shares traded during the day was 19221 in over 484 trades.

The stock hit an intraday high of Rs. 280.80 and intraday low of 265.00. The net turnover during the day was Rs. 5228079.00.